琥珀酸亚铁联合维生素C纠正宫颈癌伴贫血患者的疗效评价及安全性

Efficacy evaluation and safety observation of ferrous succinate combined with vitamin C in patients of cervical cancer with anemia

目的探究琥珀酸亚铁联合维生素C纠正宫颈癌患者贫血的临床疗效及安全性问题。方法筛选放疗科100例宫颈癌伴贫血患者作为研究对象,根据是否规范使用琥珀酸亚铁联合维生素C分为两组,实验组(n=50)采用口服琥珀酸亚铁和维生素C片进行常规治疗,对照组(n=50)未规范行抗贫血治疗。观察并分析两组患者治疗前后的血红蛋白(Hb)水平,规定Hb升高≥20 g/L或至正常值为治疗有效;同时统计两组患者胃肠道不良反应的发生情况。结果实验组患者贫血治疗的总有效率达48%,其中行术后辅助放化疗的患者总有效率为56%,行根治性放化疗的患者为40%,均明显优于对照组(P<0.05)。并且两组的胃肠道不良反应发生率差异无统计学意义(P>0.05)。结论琥珀酸亚铁联合维生素C用于治疗宫颈癌患者贫血的疗效显著,安全性可靠,临床上应在此类患者中常规、规范使用。

Objective To investigate the clinical efficacy and safety of ferrous succinate combined with vitamin C in patients of cervical cancer with anemia.Methods A total of 100 patients with cervical cancer and anemia in radiotherapy department were selected.According to whether the standard use of ferrous succinate combined with vitamin C was adopted,they were divided into two groups.The experimental group(n=50)received oral ferrous sulfate and vitamin C tablets for routine treatment,while the control group(n=50)did not receive standard anti-anemia treatment.The hemoglobin(Hb)level of 2 groups before and after treatment was observed and analyzed,and the effective treatment was defined as the increase of Hb value≥20 g/L or to the normal value.At the same time,the incidence of gastrointestinal adverse reactions in the two groups was analyzed.Results The total effective rate of anemia treatment in the experimental group was 48%,among which the total effective rate of postoperative adjuvant chemoradiotherapy was 56%,and the total effective rate of radical chemoradiotherapy was 40%,which were significantly better than the control group(P<0.05).There was no significant difference in the incidence of gastrointestinal adverse reactions between the two groups(P>0.05).Conclusion Ferrous succinate combined with vitamin C in the treatment of anemia in patients with cervical cancer has significant efficacy and is safe and reliable,so it should be routinely and standardized in clinical practice.